AVEO Pharmaceuticals Inc. (AVEO) and Hepion Pharmaceuticals Inc. (NASDAQ:CTRV) Comparison side by side

AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) and Hepion Pharmaceuticals Inc. (NASDAQ:CTRV) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AVEO Pharmaceuticals Inc. 1 18.66 N/A 0.03 23.88
Hepion Pharmaceuticals Inc. 11 0.00 N/A -81.90 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of AVEO Pharmaceuticals Inc. and Hepion Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
AVEO Pharmaceuticals Inc. 0.00% -11.1% 17.6%
Hepion Pharmaceuticals Inc. 0.00% 0% 0%

Analyst Recommendations

The Recommendations and Ratings for AVEO Pharmaceuticals Inc. and Hepion Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AVEO Pharmaceuticals Inc. 0 1 0 2.00
Hepion Pharmaceuticals Inc. 0 0 0 0.00

The average target price of AVEO Pharmaceuticals Inc. is $1, with potential upside of 2.04%.

Institutional and Insider Ownership

Roughly 31.9% of AVEO Pharmaceuticals Inc. shares are held by institutional investors while 3.72% of Hepion Pharmaceuticals Inc. are owned by institutional investors. About 0.28% of AVEO Pharmaceuticals Inc.’s share are held by insiders. Comparatively, insiders own roughly 36.42% of Hepion Pharmaceuticals Inc.’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AVEO Pharmaceuticals Inc. -10.03% -10.8% -31.77% -64.93% -70.3% -61.2%
Hepion Pharmaceuticals Inc. -7.01% -16.55% -75.65% -84.73% -94.67% -81.86%

For the past year AVEO Pharmaceuticals Inc. was less bearish than Hepion Pharmaceuticals Inc.

Summary

On 7 of the 9 factors AVEO Pharmaceuticals Inc. beats Hepion Pharmaceuticals Inc.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

ContraVir Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. The company is developing CMX157 and CRV431 to treat HBV infection; and FV-100, an orally available, small molecule compound for the prevention of post-herpetic neuralgia, and treatment of herpes zoster infection and acute zoster-associated pain. ContraVir Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Edison, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.